Skip to main content
SpringerLink
Log in

Botulinum Toxin Therapy in Medical Pain Disorders

  • Chapter
  • First Online:
Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine

  • 396 Accesses

Abstract

Animal studies have shown that local injection of botulinum neurotoxins (BoNTs) reduces neuropathic pain. This effect is exerted via interfering with the function of pain transmitters and modulators at peripheral and central levels. Recent studies in humans have demonstrated an analgesic effect in several pain disorders. In this chapter, the effect of BoNT therapy in different medical, human pain syndromes is reviewed. The level of efficacy in each pain syndrome is determined according to the guidelines of the Assessment Subcommittee of the American Academy of Neurology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8):1131–8. https://doi.org/10.1002/mds.27072.

    Article  CAS  PubMed  Google Scholar 

  2. Gronseth G, French J. Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology. 2008;71(20):1639–43. https://doi.org/10.1212/01.wnl.0000336535.27773.c0.

    Article  PubMed  Google Scholar 

  3. French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology. 2008;71(20):1634–8. https://doi.org/10.1212/01.wnl.0000336533.19610.1b.

    Article  PubMed  Google Scholar 

  4. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9. https://doi.org/10.1212/01.wnl.0000252808.97649.21.

    Article  CAS  PubMed  Google Scholar 

  5. Eller M, Goadsby PJ. Migraine: a brain state amenable to therapy. Med J Aust. 2020;212(1):32–9. https://doi.org/10.5694/mja2.50435.

    Article  PubMed  Google Scholar 

  6. Parikh SK, Silberstein SD. Preventive treatment for episodic migraine. Neurol Clin. 2019;37(4):753–70. https://doi.org/10.1016/j.ncl.2019.07.004.

    Article  PubMed  Google Scholar 

  7. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803. https://doi.org/10.1177/0333102410364676.

    Article  CAS  PubMed  Google Scholar 

  8. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14. https://doi.org/10.1177/0333102410364677.

    Article  CAS  PubMed  Google Scholar 

  9. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36. https://doi.org/10.1111/j.1526-4610.2010.01678.x.

    Article  PubMed  Google Scholar 

  10. Silberstein SD, Blumenfeld AM, Cady RK, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331(1–2):48–56. https://doi.org/10.1016/j.jns.2013.05.003.

    Article  CAS  PubMed  Google Scholar 

  11. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011;77(15):1465–72. https://doi.org/10.1212/WNL.0b013e318232ab65.

    Article  CAS  PubMed  Google Scholar 

  12. Aurora SK, Dodick DW, Diener HC, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014;129(1):61–70. https://doi.org/10.1111/ane.12171.

    Article  CAS  PubMed  Google Scholar 

  13. Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache. 2017;57(5):766–77. https://doi.org/10.1111/head.13074.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Choi YJ, Lee WJ, Lee HJ, Lee KW, Kim HJ, Hu KS. Effective botulinum toxin injection guide for treatment of temporal headache. Toxins (Basel). 2016;8(9):265. Published 2016 Sep 8. https://doi.org/10.3390/toxins8090265.

    Article  CAS  Google Scholar 

  15. Schaefer SM, Gottschalk CH, Jabbari B. Treatment of chronic migraine with focus on botulinum neurotoxins. Toxins (Basel). 2015;7(7):2615–28. Published 2015 Jul 14. https://doi.org/10.3390/toxins7072615.

    Article  CAS  Google Scholar 

  16. Richardson D, Jabbari B. Botulinum treatment of chronic migraine. A double- blind study with a novel technique employing fewer injections. Poster 124- American Academy of Neurology annual meeting, Vancouver, Canada, April 19, 2016.

    Google Scholar 

  17. Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med. 2010;11(12):1827–33. https://doi.org/10.1111/j.1526-4637.2010.01003.x.

    Article  PubMed  Google Scholar 

  18. Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857–64. https://doi.org/10.1097/AJP.0b013e31827a72d2.

    Article  PubMed  Google Scholar 

  19. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain [published correction appears in Ann Neurol. 2009;65(3):359]. Ann Neurol. 2008;64(3):274–83. https://doi.org/10.1002/ana.21427.

    Article  PubMed  Google Scholar 

  20. Attal N, de Andrade DC, Adam F, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15(6):555–65. https://doi.org/10.1016/S1474-4422(16)00017-X.

    Article  CAS  PubMed  Google Scholar 

  21. Wu CJ, Lian YJ, Zheng YK, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32(6):443–50. https://doi.org/10.1177/0333102412441721.

    Article  PubMed  Google Scholar 

  22. Zhang H, Lian Y, Ma Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014;15(1):65. Published 2014 Sep 27. https://doi.org/10.1186/1129-2377-15-65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction [published correction appears in Mayo Clin Proc. 2008;83(2):255]. Mayo Clin Proc. 2007;82(11):1341–9. https://doi.org/10.4065/82.11.1341.

    Article  PubMed  Google Scholar 

  24. Mueller D, Obermann M, Yoon MS, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia. 2011;31(15):1542–8. https://doi.org/10.1177/0333102411424619.

    Article  PubMed  Google Scholar 

  25. Li S, Lian YJ, Chen Y, et al. Therapeutic effect of botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. J Headache Pain. 2014;15(1):43. Published 2014 Jun 22. https://doi.org/10.1186/1129-2377-15-43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473–8. https://doi.org/10.1212/01.wnl.0000345968.05959.cf.

    Article  CAS  PubMed  Google Scholar 

  27. Ghasemi M, Ansari M, Basiri K, Shaigannejad V. The effects of intradermal botulinum toxin type A injections on pain symptoms of patients with diabetic neuropathy. J Res Med Sci. 2014;19(2):106–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Restivo DA, Casabona A, Frittitta L, et al. Efficacy of botulinum toxin A for treating cramps in diabetic neuropathy. Ann Neurol. 2018;84(5):674–82. https://doi.org/10.1002/ana.25340.

    Article  CAS  PubMed  Google Scholar 

  29. Salehi H, Moussaei M, Kamiab Z, Vakilian A. The effects of botulinum toxin type A injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: a randomized double-blind clinical trial. Iran J Neurol. 2019;18(3):99–107.

    PubMed  PubMed Central  Google Scholar 

  30. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56(10):1290–3. https://doi.org/10.1212/wnl.56.10.1290.

    Article  CAS  PubMed  Google Scholar 

  31. Machado D, Kumar A, Jabbari B. Abobotulinum toxin A in the treatment of chronic low back pain. Toxins (Basel). 2016;8(12):374. Published 2016 Dec 15. https://doi.org/10.3390/toxins8120374.

    Article  CAS  Google Scholar 

  32. De Andrés J, Adsuara VM, Palmisani S, Villanueva V, López-Alarcón MD. A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans. Reg Anesth Pain Med. 2010;35(3):255–60. https://doi.org/10.1097/AAP.0b013e3181d23241.

    Article  CAS  PubMed  Google Scholar 

  33. Cogné M, Petit H, Creuzé A, Liguoro D, de Seze M. Are paraspinous intramuscular injections of botulinum toxin a (BoNT-A) efficient in the treatment of chronic low-back pain? A randomised, double-blinded crossover trial. BMC Musculoskelet Disord. 2017;18(1):454. Published 2017 Nov 15. https://doi.org/10.1186/s12891-017-1816-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil. 2005;84(9):649–54. https://doi.org/10.1097/01.phm.0000176339.73591.d7.

    Article  PubMed  Google Scholar 

  35. Huang YC, Wei SH, Wang HK, Lieu FK. Ultrasonographic guided botulinum toxin type A treatment for plantar fasciitis: an outcome-based investigation for treating pain and gait changes. J Rehabil Med. 2010;42(2):136–40. https://doi.org/10.2340/16501977-0491.

    Article  PubMed  Google Scholar 

  36. Peterlein CD, Funk JF, Hölscher A, Schuh A, Placzek R. Is botulinum toxin A effective for the treatment of plantar fasciitis? Clin J Pain. 2012;28(6):527–33. https://doi.org/10.1097/AJP.0b013e31823ae65a.

    Article  PubMed  Google Scholar 

  37. Elizondo-Rodriguez J, Araujo-Lopez Y, Moreno-Gonzalez JA, Cardenas-Estrada E, Mendoza-Lemus O, Acosta-Olivo C. A comparison of botulinum toxin A and intralesional steroids for the treatment of plantar fasciitis: a randomized, double-blinded study. Foot Ankle Int. 2013;34(1):8–14. https://doi.org/10.1177/1071100712460215.

    Article  PubMed  Google Scholar 

  38. Ahmad J, Ahmad SH, Jones K. Treatment of plantar fasciitis with botulinum toxin. Foot Ankle Int. 2017;38(1):1–7. https://doi.org/10.1177/1071100716666364.

    Article  PubMed  Google Scholar 

  39. Abbasian M, Baghbani S, Barangi S, et al. Outcomes of ultrasound-guided gastrocnemius injection with botulinum toxin for chronic plantar fasciitis. Foot Ankle Int. 2020;41(1):63–8. https://doi.org/10.1177/1071100719875220.

    Article  PubMed  Google Scholar 

  40. Fishman LM, Anderson C, Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. Am J Phys Med Rehabil. 2002;81(12):936–42. https://doi.org/10.1097/00002060-200212000-00009.

    Article  PubMed  Google Scholar 

  41. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil. 2002;81(10):751–9. https://doi.org/10.1097/00002060-200210000-00006.

    Article  PubMed  Google Scholar 

  42. Fishman LM, Wilkins AN, Rosner B. Electrophysiologically identified piriformis syndrome is successfully treated with incobotulinum toxin a and physical therapy. Muscle Nerve. 2017;56(2):258–63. https://doi.org/10.1002/mus.25504.

    Article  CAS  PubMed  Google Scholar 

  43. Wong SM, Hui AC, Tong PY, Poon DW, Yu E, Wong LK. Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2005;143(11):793–7. https://doi.org/10.7326/0003-4819-143-11-200512060-00007.

    Article  CAS  PubMed  Google Scholar 

  44. Hayton MJ, Santini AJ, Hughes PJ, Frostick SP, Trail IA, Stanley JK. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Joint Surg Am. 2005;87(3):503–7. https://doi.org/10.2106/JBJS.D.01896.

    Article  CAS  PubMed  Google Scholar 

  45. Placzek R, Drescher W, Deuretzbacher G, Hempfing A, Meiss AL. Treatment of chronic radial epicondylitis with botulinum toxin A: a double-blind, placebo-controlled, randomized multicenter study. J Bone Joint Surg Am. 2007;89(2):255–60. https://doi.org/10.2106/JBJS.F.00401.

    Article  PubMed  Google Scholar 

  46. Espandar R, Heidari P, Rasouli MR, et al. Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: a randomized controlled trial. CMAJ. 2010;182(8):768–73. https://doi.org/10.1503/cmaj.090906.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Han ZA, Song DH, Oh HM, Chung ME. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol. 2016;79(4):569–78. https://doi.org/10.1002/ana.24605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Gottsch HP, Yang CC, Berger RE. A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scand J Urol Nephrol. 2011;45(1):72–6. https://doi.org/10.3109/00365599.2010.529820.

    Article  CAS  PubMed  Google Scholar 

  49. Falahatkar S, Shahab E, Gholamjani Moghaddam K, Kazemnezhad E. Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double-blind and randomized placebo-controlled study. BJU Int. 2015;116(4):641–9. https://doi.org/10.1111/bju.12951.

    Article  CAS  PubMed  Google Scholar 

  50. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8(Suppl 2):S50–62. https://doi.org/10.1111/j.1526-4637.2006.00179.x.

    Article  PubMed  Google Scholar 

  51. Boulton AJ. Diabetic neuropathy: classification, measurement and treatment. Curr Opin Endocrinol Diabetes Obes. 2007;14(2):141–5. https://doi.org/10.1097/MED.0b013e328014979e.

    Article  PubMed  Google Scholar 

  52. National Institute of Health (NIH) fact sheet 8-2019. Back Pain Fact Sheet, NINDS, Publication date March 2020. NIH Publication No. 20-NS-5161.

    Google Scholar 

  53. Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of botulinum toxin type A action on pain. Toxins (Basel). 2019;11(8):459. Published 2019 Aug 5. https://doi.org/10.3390/toxins11080459.

    Article  CAS  Google Scholar 

  54. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113(3):400–4. https://doi.org/10.3109/00016489309135834.

    Article  CAS  PubMed  Google Scholar 

  55. Nathan ST, Roberts CS, Deliberato D. Lumbar paraspinal compartment syndrome. Int Orthop. 2012;36(6):1221–7. https://doi.org/10.1007/s00264-011-1386-4.

    Article  PubMed  Google Scholar 

  56. Chandler TJ, Kibler WB. A biomechanical approach to the prevention, treatment and rehabilitation of plantar fasciitis. Sports Med. 1993;15(5):344–52. https://doi.org/10.2165/00007256-199315050-00006.

    Article  CAS  PubMed  Google Scholar 

  57. Hallin RP. Sciatic pain and the piriformis muscle. Postgrad Med. 1983;74(2):69–72. https://doi.org/10.1080/00325481.1983.11698378.

    Article  CAS  PubMed  Google Scholar 

  58. Gulledge BM, Marcellin-Little DJ, Levine D, et al. Comparison of two stretching methods and optimization of stretching protocol for the piriformis muscle. Med Eng Phys. 2014;36(2):212–8. https://doi.org/10.1016/j.medengphy.2013.10.016.

    Article  PubMed  Google Scholar 

  59. Kirschner JS, Foye PM, Cole JL. Piriformis syndrome, diagnosis and treatment. Muscle Nerve. 2009;40(1):10–8. https://doi.org/10.1002/mus.21318.

    Article  PubMed  Google Scholar 

  60. Fishman LM, Dombi GW, Michaelsen C, et al. Piriformis syndrome: diagnosis, treatment, and outcome--a 10-year study. Arch Phys Med Rehabil. 2002;83(3):295–301. https://doi.org/10.1053/apmr.2002.30622.

    Article  PubMed  Google Scholar 

  61. Jankovic D, Peng P, van Zundert A. Brief review: piriformis syndrome: etiology, diagnosis, and management. Can J Anaesth. 2013;60(10):1003–12. https://doi.org/10.1007/s12630-013-0009-5.

    Article  PubMed  Google Scholar 

  62. Cutts S, Gangoo S, Modi N, Pasapula C. Tennis elbow: a clinical review article. J Orthop. 2019;17:203–7. Published 2019 Aug 10. https://doi.org/10.1016/j.jor.2019.08.005.

    Article  PubMed  Google Scholar 

  63. Smidt N, van der Windt DA, Assendelft WJ, Devillé WL, Korthals-de Bos IB, Bouter LM. Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. Lancet. 2002;359(9307):657–62. https://doi.org/10.1016/S0140-6736(02)07811-X.

    Article  CAS  PubMed  Google Scholar 

  64. Connell D, Burke F, Coombes P, et al. Sonographic examination of lateral epicondylitis. AJR Am J Roentgenol. 2001;176(3):777–82. https://doi.org/10.2214/ajr.176.3.1760777.

    Article  CAS  PubMed  Google Scholar 

  65. Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996;87(3):321–7. https://doi.org/10.1016/0029-7844(95)00458-0.

    Article  CAS  PubMed  Google Scholar 

  66. Abdel-Meguid TA, Mosli HA, Farsi H, Alsayyad A, Tayib A, Sait M, Abdelsalam A. Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: a prospective controlled study. Can J Urol. 2018;25:9273–80.

    PubMed  Google Scholar 

  67. Safarpour Y, Jabbari B. Botulinum toxin treatment of pain syndromes -an evidence- based review. Toxicon. 2018;147:120–8. https://doi.org/10.1016/j.toxicon.2018.01.017.

    Article  CAS  PubMed  Google Scholar 

  68. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R, Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006;125(1–2):82–8. https://doi.org/10.1016/j.pain.2006.05.001.

    Article  CAS  PubMed  Google Scholar 

  69. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology. 2005;103(2):377–83. https://doi.org/10.1097/00000542-200508000-00021.

    Article  CAS  PubMed  Google Scholar 

  70. Jabbari B. Botulinum toxin Treatment- what everybody should know. New York: Springer; 2018.

    Book  Google Scholar 

  71. Jabbari B. Botulinum toxin treatment in clinical medicine – a disease-oriented approach. New York: Springer Publisher; 2018.

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Oregon Health &Science University, Portland, OR, USA

    Delaram Safarpour

  2. Department of Neurology, Yale University School of Medicine, New Haven, CT, USA

    Bahman Jabbari

Authors
  1. Delaram Safarpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bahman Jabbari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bahman Jabbari .

Editor information

Editors and Affiliations

  1. Professor Emeritus of Neurology, Yale University School of Medicine, New Haven, CT, USA

    Bahman Jabbari

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Safarpour, D., Jabbari, B. (2020). Botulinum Toxin Therapy in Medical Pain Disorders. In: Jabbari, B. (eds) Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-50691-9_6

Download citation

Publish with us

Policies and ethics

Search

Navigation